Roche stops two Huntington's disease gene-silencing programs after disappointing trial data

Roche announced it is ending development of two gene‑silencing candidates aimed at Huntington's disease after data failed to meet expectations.

The decision follows a recent readout that showed insufficient reduction of mutant huntingtin protein and no clear clinical benefit, prompting the company to reallocate resources.

Roche's move reflects broader challenges in gene‑silencing approaches for neurodegenerative disorders, and investors may view the setback as a negative signal for similar programs.

The announcement comes as ARPA‑H launches a $160 million initiative to accelerate bespoke gene‑editing therapies for rare diseases, highlighting continued interest in the field despite setbacks.